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Abstract
Rho GTPases control cell division, motility, adhesion, vesicular trafficking and phagocytosis, 
which may affect progression and/or prognosis of cancers. Here, we investigated associations 
between genetic variants of Rho GTPases-related genes and cutaneous melanoma-specific survival 
(CMSS) by re-analyzing a published melanoma genome-wide association study (GWAS) and 
validating the results in another melanoma GWAS. In the single-locus analysis of 36,018 SNPs in 
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129 Rho-related genes, 427 SNPs were significantly associated with CMSS (P<0.050 and false-
positive report probability <0.2) in the discovery dataset, and five SNPs were replicated in the 
validation dataset. Among these, four SNPs (i.e., RHOU rs10916352 G>C, ARHGAP22 
rs3851552 T>C, ARHGAP44 rs72635537 C>T and ARHGEF10 rs7826362 A>T) were 
independently predictive of CMSS (a meta-analysis derived P=9.04×10−4, 9.58×10−4, 1.21×10−4 
and 8.47×10−4, respectively). Additionally, patients with an increasing number of unfavorable 
genotypes (NUGs) of these loci had markedly reduced CMSS in both discovery dataset and 
validation dataset (Ptrend=1.47×10−7 and 3.12×10−5). The model including the NUGs and clinical 
variables demonstrated a significant improvement in predicting the five-year CMSS. Moreover, 
rs10916352C and rs3851552C alleles were significantly associated with an increased mRNA 
expression levels of RHOU (P=1.8×10−6) and ARHGAP22 (P=5.0×10−6), respectively. These 
results may provide promising prognostic biomarkers for CM personalized management and 
treatment.
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Introduction
Cutaneous melanoma (CM), one of the most lethal skin cancers, is a leading cause of cancer 
mortality in the United States. In 2017, an estimated of 87,110 new cases will be diagnosed 
and 9,730 cases will die of CM 1. Unlike several other major cancers, including lung, 
bronchus, colon and rectal cancers, that have manifested declining trends, CM has 
demonstrated a stably high mortality rate for the past two decades 2 and continues to 
represent a significant public health concern. Risk-stratified management, based on accurate 
staging systems and prognostic information, is a key in addressing CM-related mortality 3. 
However, current staging systems have insufficient discriminative power to provide accurate 
clinical prognostication of the disease 4, thus hampering personalized clinical assessment. 
Therefore, there is an urgent need to identify new prognostic indicators improved 
discriminative power.
Germline genetic variants, such as single nucleotide polymorphisms (SNPs), may provide 
additional information beyond current clinical staging and pathologic prognostic 
assessment 5. Recent years have witnessed much success of genome-wide association 
studies (GWAS) in identifying SNPs that are associated with increased CM risks 6. 
Subsequent pathway analyses of GWAS datasets have further detected several functional 
SNPs that are associated with CM survival, after adjusting for clinical and pathologic 
prognostic features, including stage, and presence of primary tumor Breslow thickness and 
ulceration. Examples of proposed prognostic SNPs include those mapped to genes involved 
in angiogenesis and lymphangiogenesis pathways 7, Fanconi anemia pathway 8, Hippo 
pathway 9, Notch pathway 10 and vitamin D pathway 11. In summary, analyzing genotyping 
data of genes functioning in pivotal biological pathways or processes can provide clues for 
molecular mechanisms underlying melanocyte carcinogenesis and CM progression.
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Rho GTPases act as a molecular switch and have been implicated in controlling cell 
division, motility, cell adhesion, vesicular trafficking as well as phagocytosis and 
transcriptional regulation 12. The activity of Rho proteins is determined by two different 
states: active GTP-bound states and inactive GDP-bound states that can be controlled by 
their regulatory proteins. Three classes of such regulatory proteins, including guanine 
nucleotide exchange factors (GEFs), upregulate Rho activity by catalyzing the exchange of 
GDP for GTP; GTPases-activating proteins (GAPs) inhibit Rho activity by stimulation of the 
GTP hydrolysis, while guanine nucleotide dissociation inhibitors (GDIs) act as molecular 
chaperones and prevent activation by sequestering GTPases away from GEFs 12.
Given their unique functions, Rho GTPases and their related regulators may be implicated in 
tumor progression. Evidence from the previous studies has indicated that deregulation of 
Rho GTPases and the related regulators is associated with cancer development, invasion and 
metastasis 13. A series of melanoma studies have shown that the Rho GTPases and the 
related regulators play a vital role in melanoma cell motility and metastasis 14, 15. 
Additionally, reports have also demonstrated that aberrant expression of CDC42, RHOC, 
GEF-H1 and DLC1 (one of the GAPs) is associated with CM survival 16–19. Given these 
findings, we hypothesized that genetic variants in genes encoding Rho GTPases and the 
related regulators would be associated with CM-specific survival (CMSS).
Materials and Methods
Study populations and genotyping data
We used a GWAS dataset from The University of Texas MD Anderson Cancer Center 
(MDACC) study as the discovery dataset and another GWAS dataset from the Nurses’ 
Health Study and the Health Professionals Follow-up Study conducted by Harvard Brigham 
and Women’s Hospital as the validation dataset. The study protocols were approved by 
Institutional Review Boards at both MDACC and Harvard Brigham and Women’s Hospital 
with a written informed consent from each of the subjects.
The MDACC discovery dataset included 858 non-Hispanic white CM patients who had 
complete information for clinical variables 8. The genotypes were called by using the 
BeadStudio algorithm at John Hopkins University Center for Inherited Disease Research. 
Genome-wide imputation was conducted with the MACH software based on the 1000 
Genomes Project, phase I v2 CEU data. SNPs with a minor allele frequency ≥ 0.05, a 
genotyping rate ≥ 95%, and Hardy-Weinberg equilibrium P-value ≥ 1×10−5 were included in 
the present study. The MDACC dataset can be accessed at the Database of Genotypes and 
Phenotypes (dbGaP: http://www.ncbi.nlm.nih.gov/gap) with an accession number 
phs000187.v1.p1.
The replication dataset from Harvard GWAS have been described previously 11, 20. 
Genotyping was performed using the Illumina HumanHap610 array. Genome-wide 
imputation was also performed using the MACH program based on the 1000 Genomes 
Project (Utah Residents with Northern and Western European Ancestry data, phase I v3). 
SNPs with imputation quality r2 ≥ 0.8 and minor allele frequency ≥ 0.05 in each study were 
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used in the present study. This led to 409 non-Hispanic white patients to be included in the 
validation and final analysis 11.
Gene and SNP selection
Based on the search of gene bases of the HUGO Gene Nomenclature Committee at the 
European Bioinformatics Institute (HGNC: http://www.genenames.org/), 20 genes encoding 
Rho GTPases, 66 genes encoding Rho GEFs and 50 genes encoding Rho GAPs were 
identified. Through the literature we used 21, we identified only three genes (ARHGDIA, 
ARHGDIB and ARHGDIG) that encode Rho GDIs in humans. In total, 129 autosome genes 
encoding the Rho GTPases and related regulators were selected after excluding nine genes in 
the X chromosome and one pseudogene (Table S1). SNPs within these 129 genes and their 
2-kb flanking regions were extracted from the MDACC dataset.
Statistical methods
CMSS was defined as the time from the diagnosis of disease to the date of CM-related death 
or the date of the last follow-up, whichever came first. Deaths with non-CM causes were 
considered censored. Cox proportional hazards regression analysis was conducted to assess 
associations between SNPs (with an additive model) and CMSS using the GenABEL 
package of R software. Although the Bonferroni method for multiple test correction can 
control the family-wise error rate efficiently, assuming that all SNPs under investigation are 
independent, it will lead to an over-correction due to a high level of correlations among 
SNPs in GWAS studies, particularly as a result of imputation that provided the majority of 
SNPs used in the present pathway-based hypothesis-driven study. Therefore, we used the 
less strident false-positive report probability (FPRP) method for multiple test correction to 
generate a better discriminatory set of SNPs from the MDACC study for further validation in 
the Harvard study 22. We assigned a prior probability of 0.1 to detect a HR of 1.5 for the 
genotypes and alleles of SNPs with an elevated risk. Only those SNPs with a FPRP value < 
0.2 were considered worthy of subsequent validation in the Harvard dataset. Linkage 
disequilibrium (LD) analysis was performed by HaploView 4.2 according to European 
populations from the 1000 Genomes Project with pairwise r2=0.6 as a cut-off value. 
Potential functions of SNPs were predicted by RegulomeDB (http://www.regulomedb.org/), 
SNPinfo Web Server (http://snpinfo.niehs.nih.gov/) and HaploReg 23. The stepwise Cox 
regression model including validated SNPs and clinical variables was performed to choose 
the independent SNPs. Pooled hazards ratio (HR) and 95% confidence interval (CI) were 
calculated by the meta-analysis using PLINK 1.07. Cochran’s Q statistics and I2 were 
carried out to access an inter-study heterogeneity. Fixed-effects models were used when no 
heterogeneity was found between two studies (Q-test P-value > 0.10 and I2 < 25.0%); 
otherwise, random-effects models were used. To evaluate the joint effects of the SNPs, we 
combined risk genotypes and risk alleles of each identified SNP into two different variables 
as the number of unfavorable genotypes (NUGs) and the number of risk alleles, respectively, 
and both were used as a genetic risk score for further analysis. Kaplan-Meier estimation of 
survival functions and Log-rank tests were used to evaluate the combined effects of risk 
genotypes on CMSS. The receiver operating characteristic (ROC) curve was performed to 
estimate area under the curve (AUC) from the logistic regression model. Delong’s test was 
perform to compare the AUCs across different models. A time-dependent ROC analysis was 
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performed with the survival ROC package of R software 24. The expression quantitative trait 
loci expression quantitative trait loci (eQTL) analysis was performed using data from the 
1000 Genomes Project and the GTEx Portal 25, 26. All analyses were performed using SAS 
(version 9.1.3; SAS Institute, Cary, NC), unless otherwise specified. Figure S1 provides the 
study flow chart, illustrating procedures of analyses performed in the present study.
Results
Basic characteristics of study populations
The present study included 858 patients from the MDACC GWAS and 409 patients from the 
Harvard GWAS (Table S2). All the subjects were non-Hispanic white. The details of clinical 
information including age, sex, tumor stage, Breslow thickness, ulceration of tumor, tumor 
cell mitotic rate and survival outcomes were available in the MDACC study, while only age, 
sex and survival outcomes were available in the Harvard study. In the MDACC study, 
slightly more patients were men (496, 57.8%) and older than 50 years old (487, 56.8%), 
having a median follow-up time of 81.1 months and 95 (11.07%) died of CM at the last 
follow-up. Univariate Cox regression analysis indicated that age, sex, stage, Breslow 
thickness, ulceration and mitotic rate were significantly associated with CMSS. In the 
Harvard study, however, much more patients were women (271, 66.3%) and older than 50 
years old (337, 82.3%), having a relatively longer median follow-up time (179 months) and 
57 (11.5%) died of CM at the last follow-up. Univariate Cox regression analysis indicated 
that only age was significantly associated with CMSS.
Survival analysis of SNPs and CMSS
As shown in Figure S1, a total of 5,289 genotyped and 30,732 imputed SNPs were extracted 
in the MDACC discovery dataset. We found that 2,453 SNPs were significantly associated 
with CMSS at P < 0.05 in the single-locus analysis with an additive genetic model by Cox 
regression analysis, in which 427 SNPs had FPRPs < 0.20. Then, those loci were further 
subjected for validation. As summarized in Table 1, five SNPs in four genes remained 
statistically significant with P < 0.05 in the Harvard study and in the same direction of 
effects as detected by the MDACC study. RHOU rs10916352, ARHGAP22 rs3851552, 
ARHGAP44 rs72635537 and ARHGEF10 rs7826362 were significantly associated with 
poorer survival, while SNP RHOU rs7555155 was associated with better survival in both 
studies. Meta-analysis confirmed that the same associations remained, and the five SNPs 
were not significantly heterogeneous in effects across the two studies.
Four independent SNPs as CM survival predictors
We further performed LD analysis of the two SNPs in RHOU, and found that they were in 
moderate LD (r2 = 0.66). Functional prediction by SNPinfo and RegulomeDB indicated that 
RHOU rs3851552, ARHGAP22 rs3851552 and ARHGEF10 rs7826362 had a RegulomeDB 
scores of 5, 6 and 5, respectively, which suggests that these SNPs may be located in the 
transcription factor binding or DNase I regulating sites (Table S3). We also searched for 
their moderate linked SNPs (r2 ≥0.60) and made further functional annotation by HaploReg 
(Table S4). For example, SNP rs7555155 may disrupt the motif of Zfp105, whereas 
rs10916352 is located in the DNase I hypersensitive sites and may disrupt the motifs of 
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Foxq1, GR and HNF1, and has a linear correlation with mRNA expression of its 
corresponding gene RHOU. Two SNPs in ARHGAP44, in a moderate linkage with our 
identified SNP rs72635537, were predicted to disrupt protein motifs. Considering all the 
functional prediction results of the five SNPs, we included RHOU rs10916352, ARHGAP22 
rs3851552, ARHGAP44 rs72635537 and ARHGEF10 rs7826362 as functional SNPs to 
build the model for CMSS prediction. They remained significantly associated with CMSS 
when included together with clinical characteristics in a stepwise Cox model in MDACC 
study (Table S5). Taken all together, we selected RHOU rs3851552, ARHGAP22 
rs3851552, ARHGAP44 rs72635537 and ARHGEF10 rs7826362 as the final independent 
SNPs for further analyses (Regional association plots were shown in Figure 1). In the 
MDACC study, risk of death was significantly increased with the number of rs10916352 C, 
rs3851552 C, rs72635537 T and rs7826362 T alleles (trend test: P = 0.012, 0.016, 0.004 and 
0.012, respectively, Table 2) and similar results were observed in the Harvard study (trend 
test: P = 0.047, 0.024, 0.018 and 0.022, respectively, Table 2). Consistently, individuals with 
genotypes of rs3851552 CC+TC, rs7263553 TT+CT and rs7826362 TT+AT had a poorer 
CMSS, compared with those harboring the wild-type genotypes of each SNP in the MDACC 
study (P = 0.004, 0.003 and 0.029, respectively) and the Harvard study (P = 0.005, 0.019 and 
0.045, respectively). However, the significant dominant effect of rs10916352 CC+GC 
genotypes was observed in the MDACC study (P = 0.003), but not in the Harvard study (P = 
0.167).
Combined effects of the four independent SNPs
For ease of interpretation of the joint effect of the four significant SNPs, we combined risk 
genotypes of rs10916352 CC+GC, rs3851552 CC+TC, rs7263553 TT+CT and rs7826362 
TT+CT into a single variable as number of unfavorable genotypes (NUGs) (Table 3). The 
trend test indicated that an increased number of NUGs was associated with an increased risk 
of death in both the MDACC (P = 1.47×10−7) and Harvard studies (P = 3.12×10−5). We 
further divided the combined NUGs into two groups: a low-risk group (0–2 NUGs) and a 
high-risk group (3–4 NUGs), and found that the hazards ratio (HRs) of death for the high-
risk group was 2.62 times [95% confidence interval (CI) = 1.73–3.96, P = 5.39×10−6] and 
2.52 times (95% CI = 1.43–4.45, P = 1.43×10−3) in the MDACC and Harvard studies, 
respectively (Table 3), when compared with the low-risk group. For the visual effect, we 
used Kaplan-Meier curves to depict associations between NUGs and CMSS (Figure 2). We 
also performed the genetic risk score analysis by using the method of simple additive 
summing up the number of risk alleles in both the MDACC and Harvard studies. As with a 
small number of events in lower and higher risk categories (Table S6), a new combined 
model was employed for survival analysis (Table S7). Individuals with either 3–4 or 5–7 risk 
alleles had an increased HR, compared with those with 0–2 risk alleles in the MDACC 
study. The trend test showed that an HR significantly increased as the number of risk alleles 
increased, which was also consistently observed in the Harvard study. Additionally, it is 
apparent that results of the combined analysis of risk alleles are very consistent with that of 
risk genotypes in the both datasets.
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Stratified analyses for associations between NUGs and CMSS
As shown in Table S8, compared with those with 0–2 NUGs, those with 2–4 NUGs had 
significantly poorer CMSS in the presence or absence of clinical variables in most of the 
stratified subgroups, except for the subgroups of metastasis and mitotic rate ≤ 1 /mm2. 
Heterogeneity was observed only in the subgroup of stage (P = 0.008).
Time dependent AUC and ROC curves for CMSS prediction
Using time-dependent AUC of the ROC curves as criteria, we further evaluated predictive 
value of the unfavorable genotypes. As shown in Figure 2, the time-dependent AUC plot 
indicated an improved prediction performance with the addition of NUGs to the model with 
clinicalpathologic factors from the beginning of the follow-up and remaining over time, 
compared with clinicalpathologic factors only. As classification of five-year CMSS, the 
AUC was significantly increased from 86.0% to 88.5% (P = 0.019), when adding NUGs to 
the clinical variables as classifiers in the ROC curve (Figure 2).
eQTLs analyses
We further conducted eQTLs analysis using data from the GTEx Portal, which only included 
RHOU rs10916352 and ARHGAP22 rs3851552 in transformed fibroblasts derived from 
donors’ tissues. Rs10916352C and rs3851552C alleles were associated with a significant 
increase in mRNA expression levels of RHOU (P = 1.8×10−6) and ARHGAP22 (P = 
5.0×10−6) in an additive genetic model (Figure 3), respectively. However, no significant 
associations were observed in 373 Europeans from the 1000 Genomes Project (data not 
shown).
Discussion
In the present study, we evaluated associations of germline genetic variants in genes 
encoding Rho GTPases and the related regulators with CMSS, using available genotyping 
data from two published CM GWAS datasets. We found that genetic variants of RHOU 
rs10916352, ARHGAP22 rs3851552, ARHGAP44 rs72635537 and ARHGEF10 rs7826362 
may individually or jointly modulate CMSS. We also observed that incorporating the 
number of NUGs of these risk SNPs significantly improved prediction accuracy of the 
model including the variables known to predict CMSS. Our results suggested the potential 
biological roles of Rho GTPases in CM progression.
The most crucial function of the Rho GTPases, which is correlated with progression of 
cancer, is the regulation of actin and cytoskeleton organization involved in cancer invasion 
and migration. The available information on the functions of Rho proteins is mostly derived 
from the study of three members: Rac1, RhoA and Cdc42. The underlying mechanisms 
include regulating the formation of lamellipodia and membrane ruffles, focal adhesion 
complexes and contractile actomyosin filaments, and formation of filopodia 27. Abnormal 
expression of RHO genes has been observed to be associated with invasion of several tumor 
types, including breast cancer, gastric carcinoma, testicular germ cell tumors, and colon 
cancer 13 as well as melanoma 19. However, no studies have reported a role of genetic 
variants encoding Rho and the related regulators in predicting clinical outcomes of cancer.
Liu et al. Page 7
Int J Cancer. Author manuscript; available in PMC 2018 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Our analysis identified four significant SNPs mapped to four genes encoding a member of 
Rho GTPases (RHOU), two members of GAPs (ARHGAP22 and ARHGAP44), and a 
member of GEFs (ARHGEF10). RHOU is upregulated by the Wnt1 signaling in Wnt1-
transformed mouse mammary cells to promote filopodium formation and stress fiber 
dissolution 28, and has been reported to regulate tumor cell invasion in prostate cancer by 
functioning similarly as the Cdc42 small GTPase 29. While ARHGAP22 and ARHGAP44 
trigger local Rac-GTP hydrolysis, thus reducing actin polymerization required for filopodia 
formation 14, 30. For example, in melanoma cell movement, ARHGAP22 can be activated to 
suppress mesenchymal movement by inactivating Rac 14. ARHGEF10 is located near a 
cancer related region, chromosome arm 8p. Loss of chromosome arm 8p has been found in 
urothelial carcinoma and other epithelial cancers and associated with more advanced tumor 
stage 31. Genetic variant in ARHGEF10 may affect the binding affinity of the Sp1 
transcriptional factor, which in turn may increase transcription of the ARHGEF10 gene, 
leading to high expression of RhoA 32. Considering these crucial biological implications, we 
inferred that the four genes may play a part in tumor progression. As the four identified 
genes hosting the four significant SNPs, respectively, we conjectured that there might be a 
strong combined effect of these four SNPs on survival of CM patients. Indeed, our analysis 
confirmed that the combined effect of the four risk genotypes outweighed that of individual 
genotypes, hinting the existence of a possible interaction network among the four genes. 
Their molecular mechanism in melanoma invasion and migration is worthy for further study.
By searching public data from the GTEx Portal, we found that variant alleles of RHOU 
rs10916352C and ARHGAP22 rs3851552C were significantly associated with mRNA 
expression levels of the corresponding genes in skin fibroblasts. This biologic evidence 
demonstrated that RHOU and ARHGAP22 expression may be mediated by these putatively 
functional SNPs, possibly explaining the associations with CMSS. It has been reported that 
other micro-environmental factors, such as endothelial cells, immune cells, soluble 
molecules, and the extracellular matrix, can interact with host fibroblasts to drive tumor 
progression and even drug resistance 33. A member of Rho GAPs, ARHGAP35, has been 
also reported to regulate expression of Cav1 in fibroblasts and facilitates remodeling of peri- 
and intra-tumoral microenvironments to promote tumor invasion 34. As the CMSS-
associated SNPs in RHOU and ARHGAP22 can modulate the expression of the 
corresponding mRNA in the skin fibroblasts, their roles in regulation of melanoma 
microenvironment are warrant to be investigated.
There are several limitations of the present study. The first limitation is the lack of complete 
clinical data in the Harvard dataset used for validation. In addition, neither of the two 
datasets had information on any systemic therapies received by the patients with an 
advanced or aggressive disease. However, no heterogeneity was observed when the two 
datasets were combined, not in the results of their meta-analysis. Second, we used a less 
stringent FPRP method to control for multiple comparisons in the discovery dataset 35. 
Although this may lead to more false positive findings, it is noteworthy that consistent 
effects of the identified SNPs on CMSS in both the discovery and validation datasets were 
observed and that two SNPs, RHOU rs10916352 and ARHGAP22 rs3851552, have potential 
functions in regulating mRNA expression. Third, although we demonstrated independent 
and combined effects of the four genetic variants on CMSS, no direct biological experiments 
Liu et al. Page 8
Int J Cancer. Author manuscript; available in PMC 2018 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
were conducted in vitro or in vivo for additional validations. Further functional 
investigations are warranted to investigate the exact function of these SNPs or genes on 
melanoma progression.
In conclusion, our present study identified the role of RHOU rs10916352, ARHGAP22 
rs3851552, ARHGAP44 rs72635537 and ARHGEF10 rs7826362 in CMSS as assessed in 
two independent GWAS datasets. Given the importance of Rho GTPases and the related 
regulators in the invasion and migration of cancer cell, these genetic variants may represent 
promising prognostic biomarkers for CM personalized management and treatment.
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Novelty and Impact
Rho GTPases control cell division, motility, adhesion, vesicular trafficking and 
phagocytosis, which may affect progression and/or prognosis of cancers. In the current 
study, we investigated associations between genetic variants of Rho GTPases-related 
genes and cutaneous melanoma survival by using datasets from two genome-wide 
association studies. Four SNPs in four genes, RHOU, ARHGAP22, ARHGAP44, and 
ARHGEF10, showed individually or jointly predicted effects on survival, suggesting a 
potential role of those genes in melanoma progression.
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Figure 1. 
Regional association plot for the independent SNPs in The University of Texas MD 
Anderson cancer Center (MDACC) dataset. Single nucleotide polymorphisms (SNPs) in the 
region of 200 kb up- or down-stream of RHOU rs10916352 (a), ARHGAP22 rs3851552 (b), 
ARHGAP44 rs72635537 (c), and ARHGEF10 rs7826362 (d). Data points are colored 
according to the level of linkage disequilibrium (LD) of each pair of SNPs based on the 
hg19/1000 Genomes European population. The left-hand y-axis shows P values for 
associations with individual SNPs, which is plotted as −log10 (P) against chromosome base-
pair position; the right-hand y-axis shows the recombination rate estimated from HapMap 
Data Rel 22/phase II European population; the selected SNPs were pointed with the red 
arrows.
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Figure 2. 
The four independent SNPs and melanoma survival. a–d. Kaplan–Meier survival curves of 
the combined risk genotypes: the exact numbers of unfavorable genotypes (NUGs) (a) in 
MDACC study and (c) in the Harvard study; dichotomized groups of the NUGs (b) in the 
MDACC study and (d) in the Harvard study. e–f. Time-dependent area under the curve 
(AUC) and receiver operating characteristic (ROC) curve estimation for prediction of 
melanoma-specific survival. (e) Time-dependent AUC estimation, based on age, sex, 
Breslow thickness, stage, ulceration, mitotic rate and the NUGs in the MDACC study and (f) 
five-year melanoma-specific survival prediction by ROC curve in the MDACC study.
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Figure 3. 
The expression quantitative trait loci analysis (eQTLs) from the Genotype-Tissue Expression 
(GTEx) project for (a) RHOU rs10916352 and (b) ARHGAP22 rs3851552 in an additive 
genetic model.
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